CSIMarket
 
Lexicon Pharmaceuticals Inc   (LXRX)
Other Ticker:  
 
 
Price: $1.7000 $0.03 1.796%
Day's High: $1.73 Week Perf: 1.8 %
Day's Low: $ 1.65 30 Day Perf: 3.66 %
Volume (M): 1,349 52 Wk High: $ 3.73
Volume (M$): $ 2,293 52 Wk Avg: $1.70
Open: $1.70 52 Wk Low: $0.92



 Market Capitalization (Millions $) 528
 Shares Outstanding (Millions) 311
 Employees 219
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -202
 Cash Flow (TTM) (Millions $) -67
 Capital Exp. (TTM) (Millions $) 0

Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc is a biopharmaceutical company that is focused on the discovery, development, and commercialization of innovative therapies for the treatment of various diseases. The company's mission is to improve patient lives by bringing breakthrough medicines to market.

The company was founded in 1995 and is headquartered in The Woodlands, Texas. It has a team of experienced professionals who have a track record of success in drug discovery and development, regulatory affairs, and commercialization.

Lexicon Pharmaceuticals has a diverse pipeline of drug candidates that are being developed for the treatment of various conditions such as diabetes, neuropathic pain, carcinoid syndrome, and irritable bowel syndrome. One of their most advanced drug candidates is sotagliflozin, which is a dual inhibitor of sodium-glucose cotransporter 1 and It is being developed as an adjunct to insulin therapy for type 1 diabetes and as a monotherapy for type 2 diabetes.

Another key drug candidate is telotristat etiprate, which is the first and only FDA-approved treatment for carcinoid syndrome diarrhea. The drug is also being developed for the treatment of refractory carcinoid syndrome and pulmonary arterial hypertension.

In addition to its robust pipeline of drug candidates, Lexicon Pharmaceuticals has strategic collaborations with pharmaceutical and biotech companies such as Sanofi, Ipsen, and Bristol-Myers Squibb. These collaborations provide additional resources and expertise to help the company advance its drug candidates and bring them to market.

Overall, Lexicon Pharmaceuticals is a well-established biopharmaceutical company with a strong commitment to developing innovative treatments for patients with unmet medical needs. Its strong pipeline and strategic collaborations position the company for continued growth and success in the future.


   Company Address: 2445 Technology Forest Blvd. The Woodlands 77381 TX
   Company Phone Number: 863-3000   Stock Exchange / Ticker: NASDAQ LXRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Sotagliflozin The Game-Changer in Diabetes Management - A Leap Towards Optimal Glycemic Control,

Published Tue, Sep 10 2024 12:00 PM UTC

'Unlocking New Potential: The Impact of Sotagliflozin on Diabetes Management'In recent developments within diabetes pharmacotherapy, new secondary analyses stemming from Phase 3 clinical trials have showcased the potential of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, in enhancing glucose control among patients with basal insulin-treated Type 2 diabetes. The findings a...

Clinical Study

INPEFA (Sotagliflozin) Shows Significant Heart Failure Benefits Across All Diabetes Durations, New Study Finds...

Published Tue, Sep 3 2024 12:01 PM UTC

Boston, October 2023 ?? A secondary analysis of Phase 3 clinical trial data on INPEFA (Sotagliflozin) has demonstrated significant benefits for heart failure patients, regardless of their diabetes duration. This research, recently published in CSIMarket.com , provides new insights into the efficacy of INPEFA in reducing critical cardiovascular events such as heart attacks, ...

Clinical Study

Sotagliflozin A Dual Approach to Elevating Care for Type 1 Diabetes Patients with Chronic Kidney Disease,

Published Wed, Aug 7 2024 12:00 PM UTC

'Exploring the Promise of Sotagliflozin: A Deep Dive into Efficacy and Safety for Type 1 Diabetes Patients with Chronic Kidney Disease'In the landscape of diabetes management, ongoing research continues to shed light on potential therapies that enhance both efficacy and safety for patients with complex comorbidities. One such therapy that has garnered attention is Sotagliflo...

Clinical Study

INPEFA (Sotagliflozin) for Heart Failure Potential Cost-Savings and Economic Impact in Alternative Payment Models

Published Mon, Jul 15 2024 12:00 PM UTC

Heart failure (HF) is a significant public health burden associated with high morbidity, mortality, and healthcare costs. The need for effective and cost-saving interventions is paramount, particularly in the context of alternative payment models (APMs) that prioritize value-based care. This article highlights the potential cost-savings and positive economic impact of INPEFA...

Clinical Study

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

Published Fri, Jun 21 2024 12:00 PM UTC

Lexicon Pharmaceuticals Resubmits NDA for Sotagliflozin Amid Compelling New Data AbstractLexicon Pharmaceuticals has resubmitted its New Drug Application (NDA) for sotagliflozin, aiming to receive approval for its use as an adjunct to insulin therapy in the management of Type 1 Diabetes (T1D) and chronic kidney disease. The submission coincides with the company's latest res...







Lexicon Pharmaceuticals Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com